Predicting Response To Platinum Chemotherapy Via Marker Of DNA Damage

Scientists have uncovered a marker of DNA damage that could predict who will respond to platinum-based chemotherapy drugs like cisplatin or carboplatin. These drugs are widely used for ovarian cancer, but as with most cancer drugs, it can be difficult to predict who will respond to therapy. A team of researchers from the Dana-Farber Cancer Institute found that this marker, telomeric allelic imbalance or tAI, could predict sensitivity to therapy in patients with triple-negative breast cancer...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/xqv8dRszQUY/243273.php

auto sport medical rehab